Eisai
's headquarters is located in Nutley, New Jersey. Eisai has been a Merger Pending of KAN Research Institute, Inc. since Oct 2023. Eisai has 8 companies in its portfolio, and its first investment was made in 2020. Eisai has 217 followers on Owler.Eisai
's headquarters is located in Nutley, New Jersey. Eisai has been a Merger Pending of KAN Research Institute, Inc. since Oct 2023. Eisai has 8 companies in its portfolio, and its first investment was made in 2020. Eisai has 217 followers on Owler.
CEO
Haruo Naito
News
Jan 13, 2026
Biospectrum Asia
Eisai: Nuvation Bio and Eisai license Taletrectinib rights outside US, China and Japan for $230 M
Jan 06, 2026
FinanzNachrichten
Eisai: BioArctic: BLA for subcutaneous formulation of Leqembi accepted in China
Dec 21, 2025
Yahoo
Eisai: Eisai (TSE:4523): Reassessing Valuation After Recent Share Price Pullback
Dec 16, 2025
FinanzNachrichten
Eisai: Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 16, 2025
South China Morning Post
Eisai: China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?
Dec 11, 2025
Pharmabiz
Eisai: NHSA of China adds generic lecanemab in its commercial insurance innovative drug list to treat early Alzheimer's disease
Dec 09, 2025
Seeking Alpha
Eisai: Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Dec 03, 2025
FinanzNachrichten
Eisai: Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Nov 28, 2025
Nasdaq
Eisai: Eisai Announces Filing Of New Drug Application For Leqembi In Japan
Nov 25, 2025
centralcharts
Press Release: Eisai : Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status